Age Range
18+
Trial Purpose
Inhloso yalolu cwaningo ukuqhathanisa i-sacituzumab tirumotecan njenge-ejenti eyodwa, futhi ngokuhambisana ne-pembrolizumab, ngokumelene ne-Treatment of Physician’s Choice (TPC) kubahlanganyeli abane-hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) engabukeki endaweni, umdlavuza webele othuthukile, noma i-metastatic.
Ama-hypotheses ayinhloko ukuthi i-sacituzumab tirumotecan njenge-ejenti eyodwa kanye ne-sacituzumab tirumotecan plus pembrolizumab ziphakeme kune-TPC ngokuphathelene nokusinda kwe-progression-free (PFS) Ngokwemibandela Yokuhlola Ukusabela ku-Solid Tumors inguqulo 1.1 (RECIST 1.1 iphuphuthekiswe i-BICR eyingxenye yonke isibuyekezo)
NATIONAL TRIAL REFERENCE NUMBER
I-NCT06312176
EU CT Number
2023-504918-29-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Trial Phase
Trial start and end dates
- Actual study start date Ephreli 14, 2024
- Estimated primary completion date Julayi 11, 2027
- Estimated study completion date Ephreli 12, 2031